NCT07448844 Intralesional Therapies For Cutaneous Viral Warts: A Comparative Analysis Of Vitamin D3 And Acyclovir
| NCT ID | NCT07448844 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Riphah International University |
| Condition | Viral Wart |
| Study Type | INTERVENTIONAL |
| Enrollment | 40 participants |
| Start Date | 2026-02-20 |
| Primary Completion | 2026-05-20 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 40 participants in total. It began in 2026-02-20 with a primary completion date of 2026-05-20.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to learn if injecting acyclovir (an antiviral drug) or vitamin D3 directly into skin warts works to clear them in people aged 12 and older with common, plantar, flat, or periungual (around the nail) warts. The main questions it aims to answer are: 1. Does intralesional acyclovir or vitamin D3 lead to complete clearance of warts by week 8? 2. Which treatment clears warts more effectively? 3. What side effects do participants have with each treatment? Researchers will compare acyclovir injections (Group A) to vitamin D3 injections (Group B), with 20 participants in each group, to see which treatment works better at clearing warts. Participants will: 1. Receive an injection directly into the wart every 2 weeks for up to 4 sessions 2. Have photographs taken of their warts before treatment and at each visit 3. Visit the clinic for checkups where the size and number of warts will be measured 4. Be followed for up to 3 months to check for wart recurrence and side effects
Eligibility Criteria
Inclusion Criteria: * Patients aged 12 years and above with clinically diagnosed cutaneous warts * Common, plantar, flat, or periungual warts * Both treatment-naïve patients and those with recalcitrant warts Exclusion Criteria: * Pregnant or lactating women * Immunocompromised patients * Individuals with history of hypersensitivity to vitamin D3 or acyclovir * Individuals receiving systemic immunosuppressive or antiviral therapy * Patients with secondary infection at injection site * Patients who had received any topical or destructive treatment for wart in previous three months
Frequently Asked Questions
Who can join the NCT07448844 clinical trial?
This trial is open to participants of all sexes, aged 12 Years or older, studying Viral Wart. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07448844 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07448844 currently recruiting?
Yes, NCT07448844 is actively recruiting participants. Visit ClinicalTrials.gov or contact Riphah International University to inquire about joining.
Where is the NCT07448844 trial being conducted?
This trial is being conducted at Rawalpindi, Pakistan, Islamabad, Pakistan.
Who is sponsoring the NCT07448844 clinical trial?
NCT07448844 is sponsored by Riphah International University. The trial plans to enroll 40 participants.